CA2710743A1 - 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use - Google Patents
5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use Download PDFInfo
- Publication number
- CA2710743A1 CA2710743A1 CA2710743A CA2710743A CA2710743A1 CA 2710743 A1 CA2710743 A1 CA 2710743A1 CA 2710743 A CA2710743 A CA 2710743A CA 2710743 A CA2710743 A CA 2710743A CA 2710743 A1 CA2710743 A1 CA 2710743A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- amino
- fluoro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 148
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 claims abstract description 37
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 claims abstract description 37
- 230000005764 inhibitory process Effects 0.000 claims abstract description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 496
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 369
- -1 C6-C10-arylcarbonyl Chemical group 0.000 claims description 356
- 125000001153 fluoro group Chemical group F* 0.000 claims description 330
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 303
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 225
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 221
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 205
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 201
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 180
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 174
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 171
- 125000001246 bromo group Chemical group Br* 0.000 claims description 165
- 229910052739 hydrogen Inorganic materials 0.000 claims description 164
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 160
- 239000001257 hydrogen Substances 0.000 claims description 158
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 156
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 124
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 121
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 110
- 229910006069 SO3H Inorganic materials 0.000 claims description 109
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 109
- 125000003277 amino group Chemical group 0.000 claims description 108
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 107
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 107
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 107
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 105
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 97
- 125000002346 iodo group Chemical group I* 0.000 claims description 85
- 229920006395 saturated elastomer Polymers 0.000 claims description 67
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 53
- 229910052731 fluorine Inorganic materials 0.000 claims description 47
- 239000011737 fluorine Substances 0.000 claims description 41
- 125000004429 atom Chemical group 0.000 claims description 40
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 39
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 150000002367 halogens Chemical class 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 26
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 25
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 17
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 15
- 239000000460 chlorine Substances 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 208000002193 Pain Diseases 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000001154 acute effect Effects 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 208000002173 dizziness Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims description 4
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical group O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- 150000004651 carbonic acid esters Chemical class 0.000 claims description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- KAWBGZHWHSUWLS-UHFFFAOYSA-N 5-(2-docosoxyethoxy)-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCCOCCCCCCCCCCCCCCCCCCCCCC)=NN1C1=CC=C(OC(F)(F)F)C=C1 KAWBGZHWHSUWLS-UHFFFAOYSA-N 0.000 claims description 2
- VSJVIQUACHURBU-UHFFFAOYSA-N 5-(2-dodecoxyethoxy)-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one 5-[2-(4-fluorophenyl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound FC1=CC=C(C=C1)CCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCCCC)OCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F VSJVIQUACHURBU-UHFFFAOYSA-N 0.000 claims description 2
- KHGCHEWQIUNUPM-UHFFFAOYSA-N 5-decoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one 3-[4-(trifluoromethoxy)phenyl]-5-undecoxy-1,3,4-oxadiazol-2-one Chemical compound C(CCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F KHGCHEWQIUNUPM-UHFFFAOYSA-N 0.000 claims description 2
- LMBZMEARFOOBKN-UHFFFAOYSA-N 5-tetradecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one 5-tridecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one Chemical compound C(CCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F LMBZMEARFOOBKN-UHFFFAOYSA-N 0.000 claims description 2
- WRIBNFPZQPQIBK-UHFFFAOYSA-N C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)F.C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC1=CC=C(C=C1)Cl Chemical compound C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)F.C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC1=CC=C(C=C1)Cl WRIBNFPZQPQIBK-UHFFFAOYSA-N 0.000 claims description 2
- GKUTVGGJHGKCOV-UHFFFAOYSA-N C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OC Chemical compound C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OC GKUTVGGJHGKCOV-UHFFFAOYSA-N 0.000 claims description 2
- PXZCFPWERGSNRL-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OC(F)(F)F.C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OC(F)(F)F.C(CCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F PXZCFPWERGSNRL-UHFFFAOYSA-N 0.000 claims description 2
- DTXJUPWTPZXFRX-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OCC1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OCC1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)[N+](=O)[O-] DTXJUPWTPZXFRX-UHFFFAOYSA-N 0.000 claims description 2
- MVYPOZQCVAAUSB-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OCC1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)F Chemical compound C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)OCC1=CC=CC=C1.C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC=C1)F MVYPOZQCVAAUSB-UHFFFAOYSA-N 0.000 claims description 2
- IVAWVFAEWBMMGH-KVVVOXFISA-N C(CCCCCCC\C=C/CCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCC)OCCOCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(CCCCCCC\C=C/CCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCC)OCCOCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F IVAWVFAEWBMMGH-KVVVOXFISA-N 0.000 claims description 2
- NBSUOFUGFICGJC-UHFFFAOYSA-N C1(=CC=CC=C1)CCCCCCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCC)OCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C1(=CC=CC=C1)CCCCCCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCC)OCCOC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F NBSUOFUGFICGJC-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- YWALCUOJNBJFIH-UHFFFAOYSA-N 5-dodecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one 5-hexadecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one 5-phenoxy-3-phenyl-1,3,4-oxadiazol-2-one Chemical compound C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.O(C1=CC=CC=C1)C1=NN(C(O1)=O)C1=CC=CC=C1 YWALCUOJNBJFIH-UHFFFAOYSA-N 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UHGSXJOONHIRAJ-UHFFFAOYSA-N 3-phenyl-1,3,4-oxadiazol-2-one Chemical class O=C1OC=NN1C1=CC=CC=C1 UHGSXJOONHIRAJ-UHFFFAOYSA-N 0.000 abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 83
- 239000000243 solution Substances 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 48
- 239000007787 solid Substances 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 37
- 239000003921 oil Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 101150041968 CDC13 gene Proteins 0.000 description 32
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 28
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 239000012267 brine Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 8
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical compound O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 150000003536 tetrazoles Chemical class 0.000 description 7
- 150000003852 triazoles Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000019502 Orange oil Nutrition 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 6
- 208000004296 neuralgia Diseases 0.000 description 6
- 239000010502 orange oil Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FNNSHABLLQXXID-UHFFFAOYSA-N (2,4-difluorophenyl) carbonochloridate Chemical compound FC1=CC=C(OC(Cl)=O)C(F)=C1 FNNSHABLLQXXID-UHFFFAOYSA-N 0.000 description 4
- GTVOSCLTRMZKQY-UHFFFAOYSA-N 3-(4-bromophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 GTVOSCLTRMZKQY-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 201000002661 Spondylitis Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- JVUGXCJIEGJVPA-UHFFFAOYSA-N 3-(3-amino-4-methoxyphenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound C1=C(N)C(OC)=CC=C1N1C(=O)OC(OC=2C(=CC(F)=CC=2)F)=N1 JVUGXCJIEGJVPA-UHFFFAOYSA-N 0.000 description 3
- HRZZXXJWVDPJBY-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(4-methoxy-3-pyrrol-1-ylphenyl)-1,3,4-oxadiazol-2-one Chemical compound COC1=CC=C(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)C=C1N1C=CC=C1 HRZZXXJWVDPJBY-UHFFFAOYSA-N 0.000 description 3
- MTEJMQRPNSGMRA-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(4-methoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)OC(OC=2C(=CC(F)=CC=2)F)=N1 MTEJMQRPNSGMRA-UHFFFAOYSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000565 sulfonamide group Chemical group 0.000 description 3
- CVRWJDIFMMZGFX-UHFFFAOYSA-N (2,4-difluorophenyl) n-(3-methoxy-4-nitroanilino)carbamate Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(NNC(=O)OC=2C(=CC(F)=CC=2)F)=C1 CVRWJDIFMMZGFX-UHFFFAOYSA-N 0.000 description 2
- BUIVYXFDCRBSLJ-UHFFFAOYSA-N (2,4-difluorophenyl) n-(3-nitroanilino)carbamate Chemical compound [O-][N+](=O)C1=CC=CC(NNC(=O)OC=2C(=CC(F)=CC=2)F)=C1 BUIVYXFDCRBSLJ-UHFFFAOYSA-N 0.000 description 2
- UBQJJNORAOGKRA-UHFFFAOYSA-N (2,4-difluorophenyl) n-(4-methoxyanilino)carbamate Chemical compound C1=CC(OC)=CC=C1NNC(=O)OC1=CC=C(F)C=C1F UBQJJNORAOGKRA-UHFFFAOYSA-N 0.000 description 2
- KEHKZXIKJFBUQB-UHFFFAOYSA-N (2,4-difluorophenyl) n-[3-(2-methoxyethoxy)-4-nitroanilino]carbamate Chemical compound C1=C([N+]([O-])=O)C(OCCOC)=CC(NNC(=O)OC=2C(=CC(F)=CC=2)F)=C1 KEHKZXIKJFBUQB-UHFFFAOYSA-N 0.000 description 2
- UWCHRDGKSBAYEL-UHFFFAOYSA-N (2-bromopyridin-3-yl) carbonochloridate Chemical compound ClC(=O)OC1=CC=CN=C1Br UWCHRDGKSBAYEL-UHFFFAOYSA-N 0.000 description 2
- WGJOQGXZLIVFNT-UHFFFAOYSA-N (2-fluoro-4-methoxyphenyl)hydrazine Chemical compound COC1=CC=C(NN)C(F)=C1 WGJOQGXZLIVFNT-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- PCZJMSVFHJMNSC-UHFFFAOYSA-N (3-methoxy-4-nitrophenyl)hydrazine Chemical compound COC1=CC(NN)=CC=C1[N+]([O-])=O PCZJMSVFHJMNSC-UHFFFAOYSA-N 0.000 description 2
- MRYIGPMJARHXEF-UHFFFAOYSA-N (4-bromo-2-methoxyphenyl) carbonochloridate Chemical compound COC1=CC(Br)=CC=C1OC(Cl)=O MRYIGPMJARHXEF-UHFFFAOYSA-N 0.000 description 2
- RYWGPCLTVXMMHO-UHFFFAOYSA-N (4-chlorophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(Cl)C=C1 RYWGPCLTVXMMHO-UHFFFAOYSA-N 0.000 description 2
- SDGDANDPHSOLAU-UHFFFAOYSA-N (4-chlorophenyl) n-(2-fluoro-4-methoxyanilino)carbamate Chemical compound FC1=CC(OC)=CC=C1NNC(=O)OC1=CC=C(Cl)C=C1 SDGDANDPHSOLAU-UHFFFAOYSA-N 0.000 description 2
- FPOSADVNKXAZSC-UHFFFAOYSA-N (4-chlorophenyl) n-(4-methoxyanilino)carbamate Chemical compound C1=CC(OC)=CC=C1NNC(=O)OC1=CC=C(Cl)C=C1 FPOSADVNKXAZSC-UHFFFAOYSA-N 0.000 description 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 2
- PLEJCMKVJYUUBA-UHFFFAOYSA-N 2-fluoro-4-methoxy-1-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(F)=C1 PLEJCMKVJYUUBA-UHFFFAOYSA-N 0.000 description 2
- YWUVOJJHVFLNJA-UHFFFAOYSA-N 2-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C(F)=C1 YWUVOJJHVFLNJA-UHFFFAOYSA-N 0.000 description 2
- YJYUCRCIUCOELZ-UHFFFAOYSA-N 3-(3-bromophenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound BrC1=CC=CC(N2C(OC(OCC=3C=CC=CC=3)=N2)=O)=C1 YJYUCRCIUCOELZ-UHFFFAOYSA-N 0.000 description 2
- RNELMFLVUYPJDS-UHFFFAOYSA-N 3-(4-amino-3-methoxyphenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one;hydrochloride Chemical compound Cl.C1=C(N)C(OC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 RNELMFLVUYPJDS-UHFFFAOYSA-N 0.000 description 2
- PHCMYOPBJGVLHU-UHFFFAOYSA-N 3-[4-(3-methoxyphenyl)phenyl]-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound COC1=CC=CC(C=2C=CC(=CC=2)N2C(OC(OC=3C=CC=CC=3)=N2)=O)=C1 PHCMYOPBJGVLHU-UHFFFAOYSA-N 0.000 description 2
- AYJCMQZJZQQNKN-UHFFFAOYSA-N 3-[4-amino-3-(2-methoxyethoxy)phenyl]-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound C1=C(N)C(OCCOC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 AYJCMQZJZQQNKN-UHFFFAOYSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- QSWFKHFKRPAQLI-UHFFFAOYSA-N 4-fluoro-2-(2-methoxyethoxy)-1-nitrobenzene Chemical compound COCCOC1=CC(F)=CC=C1[N+]([O-])=O QSWFKHFKRPAQLI-UHFFFAOYSA-N 0.000 description 2
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 2
- MDNJTHJDUWSYNN-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(3-methoxy-4-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 MDNJTHJDUWSYNN-UHFFFAOYSA-N 0.000 description 2
- JMEMDYNFCSOHJH-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(3-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound [O-][N+](=O)C1=CC=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 JMEMDYNFCSOHJH-UHFFFAOYSA-N 0.000 description 2
- ZVKKEDMQHUSSGB-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(4-methoxy-3-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1N1C(=O)OC(OC=2C(=CC(F)=CC=2)F)=N1 ZVKKEDMQHUSSGB-UHFFFAOYSA-N 0.000 description 2
- JDOYOPFKPTTWSO-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(4-pyrrol-1-ylphenyl)-1,3,4-oxadiazol-2-one Chemical compound FC1=CC(F)=CC=C1OC(OC1=O)=NN1C1=CC=C(N2C=CC=C2)C=C1 JDOYOPFKPTTWSO-UHFFFAOYSA-N 0.000 description 2
- BAQLLZGJGFFOEX-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-[3-(2-methoxyethoxy)-4-nitrophenyl]-1,3,4-oxadiazol-2-one Chemical compound C1=C([N+]([O-])=O)C(OCCOC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 BAQLLZGJGFFOEX-UHFFFAOYSA-N 0.000 description 2
- WLJYFLFRRFWBDS-UHFFFAOYSA-N 5-(4-chlorophenoxy)-3-(2-fluoro-4-methoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound FC1=CC(OC)=CC=C1N1C(=O)OC(OC=2C=CC(Cl)=CC=2)=N1 WLJYFLFRRFWBDS-UHFFFAOYSA-N 0.000 description 2
- LLNHLIUYJGQPAS-UHFFFAOYSA-N 5-(4-chlorophenoxy)-3-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(O)=CC=C1N1C(=O)OC(OC=2C=CC(Cl)=CC=2)=N1 LLNHLIUYJGQPAS-UHFFFAOYSA-N 0.000 description 2
- XSDNXVXUJJHRRO-UHFFFAOYSA-N 5-(4-chlorophenoxy)-3-(4-methoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)OC(OC=2C=CC(Cl)=CC=2)=N1 XSDNXVXUJJHRRO-UHFFFAOYSA-N 0.000 description 2
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- PLWROONZUDKYKG-DOFZRALJSA-N AACOCF3 Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)C(F)(F)F PLWROONZUDKYKG-DOFZRALJSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- KTFDGLRPFAKPFD-UHFFFAOYSA-N [3-(2-methoxyethoxy)-4-nitrophenyl]hydrazine Chemical compound COCCOC1=CC(NN)=CC=C1[N+]([O-])=O KTFDGLRPFAKPFD-UHFFFAOYSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- WFDASURDNGGLQD-UHFFFAOYSA-N benzyl N-(3-bromoanilino)carbamate Chemical compound C(C1=CC=CC=C1)OC(=O)NNC1=CC(=CC=C1)Br WFDASURDNGGLQD-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002621 endocannabinoid Substances 0.000 description 2
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- KWKZCGMJGHHOKJ-PDXKBQATSA-N methoxy arachidonyl fluorophosphonate Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCC[P@@](F)(=O)OC KWKZCGMJGHHOKJ-PDXKBQATSA-N 0.000 description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- PPHRRYCCKHYACY-UHFFFAOYSA-N (2-bromopyridin-3-yl) n-(4-methoxyanilino)carbamate Chemical compound C1=CC(OC)=CC=C1NNC(=O)OC1=CC=CN=C1Br PPHRRYCCKHYACY-UHFFFAOYSA-N 0.000 description 1
- RPYIPFXHIKXRKS-UHFFFAOYSA-N (3-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(Br)=C1 RPYIPFXHIKXRKS-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- PFNSXLDPJOLTJZ-UHFFFAOYSA-N (4-bromo-2-methoxyphenyl) n-anilinocarbamate Chemical compound COC1=CC(Br)=CC=C1OC(=O)NNC1=CC=CC=C1 PFNSXLDPJOLTJZ-UHFFFAOYSA-N 0.000 description 1
- NRESDXFFSNBDGP-UHFFFAOYSA-N (4-bromophenyl)hydrazine Chemical compound NNC1=CC=C(Br)C=C1 NRESDXFFSNBDGP-UHFFFAOYSA-N 0.000 description 1
- PMORLQFPKXVMDC-UHFFFAOYSA-N (4-methoxyanilino)carbamic acid Chemical compound COC1=CC=C(NNC(O)=O)C=C1 PMORLQFPKXVMDC-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BVOMRRWJQOJMPA-UHFFFAOYSA-N 1,2,3-trithiane Chemical compound C1CSSSC1 BVOMRRWJQOJMPA-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 1
- AMMPSAXZMLBOAN-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound FC1=CC(F)=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 AMMPSAXZMLBOAN-UHFFFAOYSA-N 0.000 description 1
- PXARYCRTGCFERN-UHFFFAOYSA-N 3-(2,5-difluorophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound FC1=CC=C(F)C(N2C(OC(OC=3C=CC=CC=3)=N2)=O)=C1 PXARYCRTGCFERN-UHFFFAOYSA-N 0.000 description 1
- COEYCIVBKOAXDQ-UHFFFAOYSA-N 3-(2-chloro-5-fluorophenyl)-5-(5-phenylpentoxy)-1,3,4-oxadiazol-2-one Chemical compound ClC1=C(C=C(C=C1)F)N1C(OC(=N1)OCCCCCC1=CC=CC=C1)=O COEYCIVBKOAXDQ-UHFFFAOYSA-N 0.000 description 1
- IDARQMJAJXLGHX-UHFFFAOYSA-N 3-(2-fluorophenyl)-5-(2-methylpropoxy)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OCC(C)C)=NN1C1=CC=CC=C1F IDARQMJAJXLGHX-UHFFFAOYSA-N 0.000 description 1
- AEBBUXFOTPGGCH-UHFFFAOYSA-N 3-(2-fluorophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound FC1=CC=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 AEBBUXFOTPGGCH-UHFFFAOYSA-N 0.000 description 1
- FURIATORBQDTMZ-UHFFFAOYSA-N 3-(2-fluorophenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound FC1=CC=CC=C1N1C(=O)OC(OCC=2C=CC=CC=2)=N1 FURIATORBQDTMZ-UHFFFAOYSA-N 0.000 description 1
- XPAYPCUUCOOPRE-UHFFFAOYSA-N 3-(2-methoxyphenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound COC1=CC=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 XPAYPCUUCOOPRE-UHFFFAOYSA-N 0.000 description 1
- QTTVWBRCSQWUJI-UHFFFAOYSA-N 3-(3-aminophenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound NC1=CC=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 QTTVWBRCSQWUJI-UHFFFAOYSA-N 0.000 description 1
- UGMTWIJCKPLKFP-UHFFFAOYSA-N 3-(3-bromophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound BrC1=CC=CC(N2C(OC(OC=3C=CC=CC=3)=N2)=O)=C1 UGMTWIJCKPLKFP-UHFFFAOYSA-N 0.000 description 1
- RRABDMDYAYIJMJ-UHFFFAOYSA-N 3-(3-chloro-2-fluorophenyl)-5-(4-methoxyphenoxy)-1,3,4-oxadiazol-2-one Chemical compound COC(C=C1)=CC=C1OC(OC1=O)=NN1C(C=CC=C1Cl)=C1F RRABDMDYAYIJMJ-UHFFFAOYSA-N 0.000 description 1
- KYUGZICWUVQVNH-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound ClC1=CC=CC(N2C(OC(OCC=3C=CC=CC=3)=N2)=O)=C1 KYUGZICWUVQVNH-UHFFFAOYSA-N 0.000 description 1
- ZEYHTAKNAUOTCO-UHFFFAOYSA-N 3-(3-fluorophenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound C(C1=CC=CC=C1)OC1=NN(C(O1)=O)C1=CC(=CC=C1)F ZEYHTAKNAUOTCO-UHFFFAOYSA-N 0.000 description 1
- RQZKOWGCZWWFBM-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound OC1=CC=CC(N2C(OC(OC=3C=CC=CC=3)=N2)=O)=C1 RQZKOWGCZWWFBM-UHFFFAOYSA-N 0.000 description 1
- CHAUTUPDVSVKET-UHFFFAOYSA-N 3-(3-nitrophenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound [O-][N+](=O)C1=CC=CC(N2C(OC(OC=3C=CC=CC=3)=N2)=O)=C1 CHAUTUPDVSVKET-UHFFFAOYSA-N 0.000 description 1
- ZZFZVOOYFNXOCR-UHFFFAOYSA-N 3-(3-nitrophenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound [O-][N+](=O)C1=CC=CC(N2C(OC(OCC=3C=CC=CC=3)=N2)=O)=C1 ZZFZVOOYFNXOCR-UHFFFAOYSA-N 0.000 description 1
- UBUDBCZCLQPTIE-UHFFFAOYSA-N 3-(4-amino-3-methoxyphenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound C1=C(N)C(OC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 UBUDBCZCLQPTIE-UHFFFAOYSA-N 0.000 description 1
- XMNHQPWIJBINBJ-UHFFFAOYSA-N 3-(4-aminophenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(N)=CC=C1N1C(=O)OC(OC=2C(=CC(F)=CC=2)F)=N1 XMNHQPWIJBINBJ-UHFFFAOYSA-N 0.000 description 1
- XEQOKWNDMZTQBZ-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-(4-methylphenoxy)-1,3,4-oxadiazol-2-one Chemical compound OC1=CC=C(C=C1)N1C(OC(=N1)OC1=CC=C(C=C1)C)=O XEQOKWNDMZTQBZ-UHFFFAOYSA-N 0.000 description 1
- HMRZPWCPYHQIGX-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound C1=CC(O)=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 HMRZPWCPYHQIGX-UHFFFAOYSA-N 0.000 description 1
- DZYJEZNBPGQWIK-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-(4-methylphenoxy)-1,3,4-oxadiazol-2-one Chemical compound COC1=CC=C(C=C1)N1C(OC(=N1)OC1=CC=C(C=C1)C)=O DZYJEZNBPGQWIK-UHFFFAOYSA-N 0.000 description 1
- WCLYGUCVWLXKDJ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-phenoxy-1,3,4-oxadiazol-2-one Chemical compound COC1=CC=C(C=C1)N1C(OC(=N1)OC1=CC=CC=C1)=O WCLYGUCVWLXKDJ-UHFFFAOYSA-N 0.000 description 1
- SKFYAIMZAJMXPX-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)OC(OCC=2C=CC=CC=2)=N1 SKFYAIMZAJMXPX-UHFFFAOYSA-N 0.000 description 1
- CSSGKHVRDGATJL-UHFFFAOYSA-N 3-fluoro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(F)=C1 CSSGKHVRDGATJL-UHFFFAOYSA-N 0.000 description 1
- FHELGJZMMHCLSX-UHFFFAOYSA-N 3-phenoxy-1,3,4-oxadiazol-2-one Chemical compound O(C1=CC=CC=C1)N1C(OC=N1)=O FHELGJZMMHCLSX-UHFFFAOYSA-N 0.000 description 1
- CQWDYNXSBWRSIW-UHFFFAOYSA-N 3-phenyl-5-(4-phenylmethoxyphenoxy)-1,3,4-oxadiazol-2-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)OC=1OC(C=C1)=CC=C1OCC1=CC=CC=C1 CQWDYNXSBWRSIW-UHFFFAOYSA-N 0.000 description 1
- HZKBDLKRLCORDJ-UHFFFAOYSA-N 3-phenyl-5-phenylmethoxy-1,3,4-oxadiazol-2-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)OC=1OCC1=CC=CC=C1 HZKBDLKRLCORDJ-UHFFFAOYSA-N 0.000 description 1
- INRZBJDXLSXUAG-UHFFFAOYSA-N 3-pyridin-3-yloxy-1,3,4-oxadiazol-2-one Chemical compound N1=CC(=CC=C1)ON1C(OC=N1)=O INRZBJDXLSXUAG-UHFFFAOYSA-N 0.000 description 1
- UNTNRNUQVKDIPV-UHFFFAOYSA-N 3h-dithiazole Chemical compound N1SSC=C1 UNTNRNUQVKDIPV-UHFFFAOYSA-N 0.000 description 1
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 description 1
- SKGFSLODAOOJTL-UHFFFAOYSA-N 4-(2-oxo-5-phenoxy-1,3,4-oxadiazol-3-yl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1N1C(=O)OC(OC=2C=CC=CC=2)=N1 SKGFSLODAOOJTL-UHFFFAOYSA-N 0.000 description 1
- AQTLDHJCTUUZNP-UHFFFAOYSA-N 4-(2-oxo-5-phenoxy-1,3,4-oxadiazol-3-yl)benzonitrile Chemical compound N=1N(C=2C=CC(=CC=2)C#N)C(=O)OC=1OC1=CC=CC=C1 AQTLDHJCTUUZNP-UHFFFAOYSA-N 0.000 description 1
- RTXCBMWDPAUZNJ-UHFFFAOYSA-N 4-(2-oxo-5-phenylmethoxy-1,3,4-oxadiazol-3-yl)benzonitrile Chemical compound N=1N(C=2C=CC(=CC=2)C#N)C(=O)OC=1OCC1=CC=CC=C1 RTXCBMWDPAUZNJ-UHFFFAOYSA-N 0.000 description 1
- WHSIIJQOEGXWSN-UHFFFAOYSA-N 4-bromo-2-methoxyphenol Chemical compound COC1=CC(Br)=CC=C1O WHSIIJQOEGXWSN-UHFFFAOYSA-N 0.000 description 1
- QPQKUYVSJWQSDY-UHFFFAOYSA-N 4-phenyldiazenylaniline Chemical compound C1=CC(N)=CC=C1N=NC1=CC=CC=C1 QPQKUYVSJWQSDY-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- YFCCNGFWSYXYKD-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-3-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(O)=CC=C1N1C(=O)OC(OC=2C(=CC(F)=CC=2)F)=N1 YFCCNGFWSYXYKD-UHFFFAOYSA-N 0.000 description 1
- AEFAJMNCKMCZGM-UHFFFAOYSA-N 5-(2-bromopyridin-3-yl)oxy-3-(4-methoxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)OC(OC=2C(=NC=CC=2)Br)=N1 AEFAJMNCKMCZGM-UHFFFAOYSA-N 0.000 description 1
- HBMRBPXSDVLIGH-UHFFFAOYSA-N 5-(4-bromo-2-methoxyphenoxy)-3-phenyl-1,3,4-oxadiazol-2-one Chemical compound COC1=CC(Br)=CC=C1OC(OC1=O)=NN1C1=CC=CC=C1 HBMRBPXSDVLIGH-UHFFFAOYSA-N 0.000 description 1
- NEIJHABNKRJMLU-UHFFFAOYSA-N 5-(4-chlorophenoxy)-3-(2-fluoro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-one Chemical compound FC1=CC(O)=CC=C1N1C(=O)OC(OC=2C=CC(Cl)=CC=2)=N1 NEIJHABNKRJMLU-UHFFFAOYSA-N 0.000 description 1
- HIJULCLFDROENT-UHFFFAOYSA-N 5-phenoxy-3-(3-phenylphenyl)-1,3,4-oxadiazol-2-one Chemical compound N=1N(C=2C=C(C=CC=2)C=2C=CC=CC=2)C(=O)OC=1OC1=CC=CC=C1 HIJULCLFDROENT-UHFFFAOYSA-N 0.000 description 1
- XNHDNZWZMRKIQR-UHFFFAOYSA-N 5-phenoxy-3-phenyl-1,3,4-oxadiazol-2-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)OC=1OC1=CC=CC=C1 XNHDNZWZMRKIQR-UHFFFAOYSA-N 0.000 description 1
- QZIFKGNYQJKORM-UHFFFAOYSA-N 5-phenylmethoxy-3-(3-phenylphenyl)-1,3,4-oxadiazol-2-one Chemical compound N=1N(C=2C=C(C=CC=2)C=2C=CC=CC=2)C(=O)OC=1OCC1=CC=CC=C1 QZIFKGNYQJKORM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- UTAXWUVFWZDMQY-UHFFFAOYSA-N C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC(=C1)Cl)Cl.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=C(C=C1)Cl)Cl Chemical compound C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=CC(=C1)Cl)Cl.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC(=C(C=C1)Cl)Cl UTAXWUVFWZDMQY-UHFFFAOYSA-N 0.000 description 1
- WXXUQHSKSRUSJM-UHFFFAOYSA-N C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.O(C1=CC=CC=C1)C=1C=C(OC2=NN(C(O2)=O)C2=CC=C(C=C2)OC(F)(F)F)C=CC1 Chemical compound C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.O(C1=CC=CC=C1)C=1C=C(OC2=NN(C(O2)=O)C2=CC=C(C=C2)OC(F)(F)F)C=CC1 WXXUQHSKSRUSJM-UHFFFAOYSA-N 0.000 description 1
- NNDNJKVISMGWPO-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C(CCCCCCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F.C(CCCCCCCCCCC)OC1=NN(C(O1)=O)C1=CC=C(C=C1)OC(F)(F)F NNDNJKVISMGWPO-UHFFFAOYSA-N 0.000 description 1
- HOHNKVUFGVNFBX-UHFFFAOYSA-N C1(=CC=CC=C1)OC(=O)NNC1=CC=C(C=C1)Br Chemical compound C1(=CC=CC=C1)OC(=O)NNC1=CC=C(C=C1)Br HOHNKVUFGVNFBX-UHFFFAOYSA-N 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- JNSAWGNVZMPYJI-UHFFFAOYSA-N CCNS(=O)=O Chemical compound CCNS(=O)=O JNSAWGNVZMPYJI-UHFFFAOYSA-N 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- KCGKYAORRXGWMN-UHFFFAOYSA-N CNS(=O)=O Chemical compound CNS(=O)=O KCGKYAORRXGWMN-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- JKVGPZANWWPSSR-UHFFFAOYSA-N ClC1=C(CCOC2=NN(C(O2)=O)C2=C(C=CC=C2)F)C=CC=C1 Chemical compound ClC1=C(CCOC2=NN(C(O2)=O)C2=C(C=CC=C2)F)C=CC=C1 JKVGPZANWWPSSR-UHFFFAOYSA-N 0.000 description 1
- VIOGVINIMRYYOB-UHFFFAOYSA-N ClC1=C(OC2=NN(C(O2)=O)C2=CC(=CC=C2)OC)C=CC=C1 Chemical compound ClC1=C(OC2=NN(C(O2)=O)C2=CC(=CC=C2)OC)C=CC=C1 VIOGVINIMRYYOB-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- VYADISSCUXPUHP-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)N1C(OC(=N1)OCCCCCC1=CC=CC=C1)=O Chemical compound NS(=O)(=O)C1=CC=C(C=C1)N1C(OC(=N1)OCCCCCC1=CC=CC=C1)=O VYADISSCUXPUHP-UHFFFAOYSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JVRHADZWRWBICE-UHFFFAOYSA-N O=S(=O)NC1=CC=CC=C1 Chemical compound O=S(=O)NC1=CC=CC=C1 JVRHADZWRWBICE-UHFFFAOYSA-N 0.000 description 1
- OSVKVLHOTJRGNS-UHFFFAOYSA-N OC1=CC=C(C=C1)N1C(OC(=N1)OCCCCCCC1=CC=CC=C1)=O Chemical compound OC1=CC=C(C=C1)N1C(OC(=N1)OCCCCCCC1=CC=CC=C1)=O OSVKVLHOTJRGNS-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- MNQDKWZEUULFPX-UHFFFAOYSA-M dithiazanine iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1C=CC=CC=C1N(CC)C2=CC=CC=C2S1 MNQDKWZEUULFPX-UHFFFAOYSA-M 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- BKOYKMLGFFASBG-UHFFFAOYSA-N hydron;(3-nitrophenyl)hydrazine;chloride Chemical compound Cl.NNC1=CC=CC([N+]([O-])=O)=C1 BKOYKMLGFFASBG-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000005185 naphthylcarbonyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029986 neuroepithelioma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005064 octadecenyl group Chemical group C(=CCCCCCCCCCCCCCCCC)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- GMQOZFVOGGIFIX-UHFFFAOYSA-N oxathiazolidine Chemical compound C1COSN1 GMQOZFVOGGIFIX-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 201000003774 sarcomatosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US930207P | 2007-12-27 | 2007-12-27 | |
| US61/009,302 | 2007-12-27 | ||
| PCT/PT2008/000054 WO2009084970A1 (en) | 2007-12-27 | 2008-12-23 | 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2710743A1 true CA2710743A1 (en) | 2009-07-09 |
Family
ID=40361548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2710743A Abandoned CA2710743A1 (en) | 2007-12-27 | 2008-12-23 | 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2238131A1 (pt) |
| JP (1) | JP2011507952A (pt) |
| KR (1) | KR20100111691A (pt) |
| CN (1) | CN101959881A (pt) |
| AR (1) | AR069970A1 (pt) |
| AU (1) | AU2008344032A1 (pt) |
| BR (1) | BRPI0821482A2 (pt) |
| CA (1) | CA2710743A1 (pt) |
| CL (1) | CL2008003895A1 (pt) |
| IL (1) | IL206419A0 (pt) |
| MX (1) | MX2010006995A (pt) |
| TW (1) | TW200932732A (pt) |
| WO (1) | WO2009084970A1 (pt) |
| ZA (1) | ZA201005306B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201028406A (en) * | 2008-12-23 | 2010-08-01 | Bial Portela & Ca Sa | 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| WO2010151160A1 (en) * | 2009-06-24 | 2010-12-29 | Bial - Portela & Ca., S.A. | O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931843A1 (de) * | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
| DE19942354A1 (de) * | 1999-09-04 | 2001-03-08 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln |
| AU2002347985A1 (en) * | 2001-11-15 | 2003-06-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| DE10208987A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| US20090111778A1 (en) * | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
-
2008
- 2008-12-23 EP EP08866782A patent/EP2238131A1/en not_active Withdrawn
- 2008-12-23 AU AU2008344032A patent/AU2008344032A1/en not_active Abandoned
- 2008-12-23 JP JP2010540610A patent/JP2011507952A/ja not_active Withdrawn
- 2008-12-23 WO PCT/PT2008/000054 patent/WO2009084970A1/en active Application Filing
- 2008-12-23 CN CN2008801276810A patent/CN101959881A/zh active Pending
- 2008-12-23 BR BRPI0821482-4A patent/BRPI0821482A2/pt not_active IP Right Cessation
- 2008-12-23 MX MX2010006995A patent/MX2010006995A/es not_active Application Discontinuation
- 2008-12-23 CL CL2008003895A patent/CL2008003895A1/es unknown
- 2008-12-23 KR KR1020107015516A patent/KR20100111691A/ko not_active Application Discontinuation
- 2008-12-23 AR ARP080105707A patent/AR069970A1/es unknown
- 2008-12-23 TW TW097150238A patent/TW200932732A/zh unknown
- 2008-12-23 CA CA2710743A patent/CA2710743A1/en not_active Abandoned
-
2010
- 2010-06-16 IL IL206419A patent/IL206419A0/en unknown
- 2010-07-26 ZA ZA2010/05306A patent/ZA201005306B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2238131A1 (en) | 2010-10-13 |
| KR20100111691A (ko) | 2010-10-15 |
| AU2008344032A1 (en) | 2009-07-09 |
| CN101959881A (zh) | 2011-01-26 |
| AR069970A1 (es) | 2010-03-03 |
| AU2008344032A8 (en) | 2010-08-19 |
| MX2010006995A (es) | 2010-08-18 |
| WO2009084970A1 (en) | 2009-07-09 |
| JP2011507952A (ja) | 2011-03-10 |
| CL2008003895A1 (es) | 2010-06-25 |
| TW200932732A (en) | 2009-08-01 |
| IL206419A0 (en) | 2010-12-30 |
| ZA201005306B (en) | 2011-04-28 |
| BRPI0821482A2 (pt) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1252156B1 (en) | Blockade of voltage dependent sodium channels | |
| JP3001620B2 (ja) | ５ｈ―フラン―２―オン誘導体 | |
| JP2008505874A (ja) | 呼吸器疾患処置用の置換酸 | |
| CA2710743A1 (en) | 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use | |
| EP2763681B1 (en) | Malignant and non-malignant disease treatment with ras antagonists | |
| CN102333568A (zh) | 药物化合物 | |
| JP2013533283A (ja) | Ｇｐｒ４０のアゴニスト | |
| US6984645B2 (en) | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein | |
| WO1995024398A1 (en) | Isoxazoline compounds as inhibitors of tnf release | |
| DK173261B1 (da) | Trisubstitueret benzoesyrederivat | |
| WO2006071471A2 (en) | 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | |
| FR2993563A1 (fr) | Derives de thiophenes utiles dans le traitement du diabete | |
| JPWO2005026127A1 (ja) | プラスミノゲンアクチベータインヒビター−１阻害剤 | |
| NZ541148A (en) | Aryl alkyl carbamate derivatives production and use thereof in therapy | |
| MX2008015485A (es) | Carboxamidas sustituidas. | |
| AU9446298A (en) | Novel 3,4-diarylthiazolin-2-one or -2-thione derivatives, preparation methods and uses in therapy | |
| JP3810838B2 (ja) | 除草性イソオキサゾリン誘導体 | |
| HU211520A9 (en) | Tetrazole derivatives and aldose reductase inhibition therewith | |
| JPH0374375A (ja) | 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類 | |
| JP3856829B2 (ja) | オキサゾリジノン誘導体、その製造及び治療的使用 | |
| US5100910A (en) | Aryl substituted tetrazole derivatives, and application thereof in therapeutics | |
| WO2008129129A1 (en) | Heterocyclic phenyl carbamates as novel faah-inhibitors | |
| JP2020158391A (ja) | 新規ニトロカテコール誘導体 | |
| WO2010074587A2 (en) | 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use | |
| US4517010A (en) | 2-Nitro-5(substituted-phenoxy) benzoyl derivatives as herbicides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20121224 |